Lantern Pharma Inc. (LTRN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 8, 2024, announces the upcoming release of financial results for the second quarter ended June 30, 2024. Lantern Pharma Inc., a Delaware corporation and emerging growth company, is scheduled to host a conference call and live webinar on August 8, 2024, to discuss these results and provide updates on its clinical trials.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of the release of such data rather than containing the data itself. Detailed financial metrics are contained in the press release furnished as Exhibit 99.1.
Material Changes and Clinical Updates
While specific financial changes are not detailed in this text, the filing highlights a significant operational update regarding the Company's product candidate LP-300. The Company will present information concerning the Harmonic Phase 2 clinical trial during the August 8, 2024, conference call. This information is furnished as Exhibit 99.3.
Guidance, Outlook, and Risks
The filing does not contain explicit forward-looking guidance, management commentary on future performance, or a detailed risk assessment within the body of the 8-K. The presentation materials (Exhibit 99.2) and the press release (Exhibit 99.1) are referenced as the sources for management's discussion and analysis. The filing includes standard disclaimers stating that the information in Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2024 revenue, net loss, and cash position figures.
- Examine Exhibit 99.3 for detailed data and endpoints from the Harmonic Phase 2 clinical trial for LP-300.
- Listen to the August 8, 2024, conference call or review Exhibit 99.2 for management's outlook and strategic updates.
- Verify the Company's cash runway and burn rate in the full quarterly report to assess liquidity needs.